Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01577095 | Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy | PHASE2 | COMPLETED | 49 | — | — | Apr 1, 2006 | May 1, 2007 | Apr 13, 2012 | 1 | Taiwan |
The primary endpoint with respect to plasma glucose level after treatment in each group of patients and compare the hypoglycemic activity between these two independent groups.
| Arm | Type | Description |
|---|---|---|
| EA + Rosiglitazone | EXPERIMENTAL | - |
| Rosiglitazone | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| EA + Rosiglitazone | OTHER | electroacupuncture and Rosiglitazone combined therapy on patient of type II DM |
| TZD | DRUG | Rosiglitazone 8 mg single dose |
Inclusion Criteria: * all included native Taiwanese patients, age from 20 to 65 years who diagnosed with type 2 diabetes mellitus within 5 years and keep the same anti-hyperglycemic agents for control diabetes before and during the period in this study * compatible with the diagnostic criteria of d...